CT imaging phenotypes linked to CA125 and HE4 biomarkers are highly predictive in discriminating between hereditary and sporadic ovarian cancer patients.

Autor:	Manganaro L; Department of Radiological, Oncological and Pathological Sciences, 'Sapienza' University of Rome, Rome, Italy., Celli V; Department of Radiological, Oncological and Pathological Sciences, 'Sapienza' University of Rome, Rome, Italy., Viggiani V; Department of Molecular Medicine, 'Sapienza' University of Rome, Rome, Italy., Berardelli E; Department of Experimental Medicine 'Sapienza' University of Rome, Rome, Italy., Granato T; CNR-IBPM, National Research Council, Institute of Molecular Biology and Pathology, Rome, Italy., Tartaglione S; Department of Experimental Medicine 'Sapienza' University of Rome, Rome, Italy., Farina A; Department of Experimental Medicine 'Sapienza' University of Rome, Rome, Italy., Catalano C; Department of Radiological, Oncological and Pathological Sciences, 'Sapienza' University of Rome, Rome, Italy., Angeloni A; Department of Experimental Medicine 'Sapienza' University of Rome, Rome, Italy., Anastasi E; Department of Experimental Medicine 'Sapienza' University of Rome, Rome, Italy.
Jazyk:	angličtina
Zdroj:	Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine [Tumour Biol] 2022; Vol. 44 (1), pp. 171-185.
DOI:	10.3233/TUB-211557
Abstrakt:	Background: Hereditary ovarian cancers (HOC) represent about 23% of ovarian cancer (OC) cases: they are most frequently related to germline mutations in the BRCA genes. Objective: We aimed to compare CA125/HE4 serum levels and Computed Tomography (CT) features at time of ovarian cancer (OC) diagnosis in two populations: BRCA mutant and BRCA wild-type (WT) OC, and to investigate the relationship between this laboratory and radiological biomarker and BRCA mutation status. Methods: This retrospective study included 60 newly diagnosed OC patients with FIGO stage IIIC-IV disease, tested for BRCA1/2 germline mutation status of which preoperative CT scan and serum tumor marker assay were available. Results: The median level of CA125 (708 U/mL) was significantly higher (p < 0.002) in BRCA1/2 mutated patients than in WT patients (176 U/mL), whereas the median level of HE4 (492 pmol/L) was significantly higher (p < 0.002) in WT than in BRCA-mutated patients (252 pmol/L). BRCA mutation carriers showed a higher incidence of bilateral ovarian masses (p = 0.0303) characterized by solid structures (p < 0.00001), higher peritoneal tumor load, macronodular implants >2 cm (p = 0.000099), increased frequency of lymphadenopathies (p = 0.019), and metastasis (p = 0.052) compared to patients with BRCA WT. Conclusions: Tumor markers and CT patterns may help in identifying BRCA mutation status in OC directing patients towards a personalized treatment.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu